Solidifying Our Understanding of the Natural History of Subsolid Pulmonary Nodules–Are We There Yet?
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
PD-L1 Expression in Lung Cancer
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study
A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer
The State of Lung Cancer Research: A Global Analysis
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR -Activating Mutation
Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas
The Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non–Small Cell Lung Cancer
Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer
Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe
Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months
Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer
Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Prediction of Early Death in Patients with Early-Stage NSCLC—Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes
G48A, a New KRAS Mutation Found in Lung Adenocarcinoma
Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report
Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification
Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib
Correction: “From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers”
Location of the Tumor is a “Central” Predictor of Nodal (N1) Upstaging
Nodal Upstaging: “Confounded” by Tumor Location?
Tissue Is the Issue for Diagnosis of EGFR T790M Mutation
Reliability Assurance of EML4-ALK Rearrangement Detection in Non–Small Cell Lung Cancer: A Methodological and Statistical Issue
Authors’ Response to Letter “Reliability Assurance of EML4-ALK Rearrangement Detection in Non–Small Cell Lung Cancer: A Methodological and Statistical Issue”